FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Resources - All Kinds, Realm US, Authority Hl7

19,367 resources (JSON | CSV)

Type:
Text: Package: Only Show Used

By Version

 

Start Prev Rows 11600 - 11800 Next

PackageVersionIdentityName/TitleStatusFMMWGDateUsage #
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.368.jsonMorbid Obesityactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.369.jsonUnavailability of Bacillus Calmette Guerin for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.370.jsonUrinary Retentionactive2025-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.371.jsonUrinary Retentionactive2025-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.372.jsonUrinary Retentionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.374.jsonFace to Face Interactionactive2025-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.375.jsonFace to Face Interactionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.376.jsonHIV Viral Load Testsactive2025-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.377.jsonHIV Viral Load Testsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.389.jsonSyphilis Testsactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.4.jsonNephrectomyactive2023-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.8.jsonLarge Body Surface Area (BSA) Burnsactive2022-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1250.2.jsonPsychological Neuropsychological or Neurobehavioral Testingactive2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1250.3.jsonPsychological or Neuropsychological Testingactive2023-111
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1251.10.jsonTricuspid Valve Regurgitationactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1251.2.jsonValvular Heart Diseaseactive2022-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1258.1.jsonGonorrhea Screeningactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1258.2.jsonAbnormal Weight Lossactive2024-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.2.jsonPrescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.3.jsonPrescribable brand and generic insulins and analoguesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.4.jsoneGFR Using 2021 Race Free Formulasactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.5.jsonFructosamine in Serum or Plasmaactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.6.jsonGlucose tests in venous blood, capillary blood, serum/plasma for Diabetesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.7.jsonCreatinine in serum/plasmaactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.9.jsonIgE Agonists, prescribableactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.10.jsonEstrogen Receptor Testing for Orserduactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.100.jsonMMR Proficientactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.101.jsonSystemic Cancer Directed Therapyactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.102.jsonFace To Face Interactionactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.104.jsonErdafitinibactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.107.jsonChemotherapy Encounteractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.108.jsonUrothelial Cancers ICD9active2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.109.jsonUrothelial Cancer ICD10active2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.110.jsonUrothelial Cancersactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.111.jsonPrior Therapies for Erdafitinibactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.112.jsonUrothelial Cancer Histologiesactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.113.jsonMalignant Tumor Behavioractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.114.jsonLocalized Bladder Cancer Stage SNOMEDactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.116.jsonLocalized Bladder Cancer Stagingactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.117.jsonAdvanced Bladder Cancer Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.118.jsonLocalized Bladder Cancer T Stageactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.119.jsonLocalized Bladder Cancer T Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.120.jsonLocalized Bladder Cancer N Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.121.jsonLocalized Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.122.jsonAdvanced Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.124.jsonLocoregional Urothelial Cancer ICD9active2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.125.jsonLocoregional Urothelial Cancer ICD10active2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.126.jsonLocoregional Urothelial Cancer SNOMEDactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.127.jsonLocoregional Urothelial Canceractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.128.jsonFGFR3 Geneactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.129.jsonFGFR3 Gene Interpretation Positive SNOMEDactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.130.jsonFGFR3 Gene Interpretation Positive LOINCactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.131.jsonFGFR3 Gene Interpretation Positive NCIactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.133.jsonFGFR3 Gene Interpretation Positiveactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.134.jsonFGFR3 Gene Interpretation Negative SNOMEDactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.135.jsonFGFR3 Gene Interpretation Negative NCIactive2024-021
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.137.jsonFGFR3 Gene Interpretation Negativeactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.138.jsonFGFR3 Molecular Variantsactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.139.jsonTumor Behavioractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.140.jsonPhyscological Support for Canceractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.141.jsonReferral For Pain From Canceractive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.142.jsonCancer Pain Educationactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.143.jsonTelehealth Encountersactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.144.jsonPain Assessment Scoreactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.146.jsonTelehealth Encounters SNOMEDCTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.147.jsonTelehealth Encounters CPTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.148.jsonTelehealth Encounters HCPCSactive2024-032
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.149.jsonTelehealth Encounters Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.150.jsonChemo Admin SNOMEDCTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.151.jsonChemo Admin CPTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.152.jsonChemo Admin HCPCSactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.153.jsonChemotherapy Administration Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.154.jsonRadiation Treatment CPTactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.155.jsonRadiation Treatment HCPCSactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.156.jsonRadiation Treatment SNOMEDCTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.157.jsonRadiation Treatment Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.158.jsonBipolar Diagnosis Codesactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.159.jsonTelephone Visits SNOMEDactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.160.jsonTelephone Visit CPTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.161.jsonTelephone Visits Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.162.jsonAdolescent depression screening assessmentactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.163.jsonAdult depression screening assessment LOINCactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.165.jsonReferral for Depression Adultactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.166.jsonReferrals for Adolescent Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.167.jsonFollow Ups for Adolescent Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.168.jsonFollowUps for Adult Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.169.jsonDepression Screen Declined for Medical Reasonactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.170.jsonPhysical Therapy Evaluations SNOMEDCTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.171.jsonPhysical Therapy Evaluation CPTactive2024-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.172.jsonPhysical Therapies Evaluationsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.173.jsonNon Opioid Analgesicsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.174.jsonAdjuvant Analgesicsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.176.jsonLung Cancer ICD9active2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.177.jsonLung Cancer ICD10active2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.178.jsonLung Canceractive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.179.jsonPrior Therapies for Osimertinibactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.18.jsonStage IAactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.181.jsonPlan of Care for Painactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.182.jsonAll Antineoplastic Agentsactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.183.jsonLocally Advanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.185.jsonLocalized NSCLC Stage Group SNOMEDactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.186.jsonRadiation Treatment Managementactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.187.jsonPlan of Careactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.188.jsonDocumentation of Plan of Careactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.189.jsonPain Presentactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.19.jsonStage IBactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.190.jsonLocalized NSCLC Stage Group NCIMactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.192.jsonLocalized NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.193.jsonAdvanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.194.jsonNSCLC M Stage (metastatic)active2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.195.jsonNSCLC T Stageactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.196.jsonNSCLC N Stageactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.197.jsonSCLC and rarer lung cancer histologyactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.198.jsonEGFR Geneactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.199.jsonEGFR Gene Interpretation Positive SNOMEDactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.20.jsonStage IIAactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.200.jsonEGFR Gene Interpretation Positive LOINCactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.201.jsonEGFR Gene Interpretation Positiveactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.202.jsonEGFR Osimertinib Molecular Variantsactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.203.jsonEGFR Generic Molecular Variant NCIMactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.204.jsonEGFR Generic Molecular Variant SNOMEDactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.205.jsonEGFR Generic Molecular Variant LOINCactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.206.jsonEGFR Molecular Variants Osimertinib PMactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.207.jsonOsimertinibactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.208.jsonPemetrexedactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.209.jsonRadiation Treatment Management SNOMEDCTactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.21.jsonStage IIBactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.210.jsonRadiation Treatment Management Codesactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.211.jsonRadiation Treatment Delivery CPTactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.212.json77427 Management Codeactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.213.jsonRadiation Treatment Delivery HCPCSactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.214.jsonRadiation Treatment Delivery NCIMactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.215.jsonRadiation Treatment Delivery SNOMEDactive2024-041
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.216.jsonRadiation Treatment Deliveryactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.217.jsonMET Gene Testactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.219.jsonTepotinibactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.22.jsonStage IIIAactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.220.jsonMET Positive gene interpretationactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.227.jsonMET Exon 14 skipping molecular variantactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.23.jsonStage IIIBactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.233.jsontest43active2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.234.jsonROS1 Molecular Variants Repotrectinib PMactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.235.jsonROS1 Repotrectinib Molecular Variantsactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.236.jsonROS1 Negative (geneinterpretation) SNOMEDCTactive2024-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.237.jsonROS1 Negative (geneinterpretation) NCIactive2024-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.238.jsonROS1 Negative (geneinterpretation) SNOMEDCT,NCIactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.239.jsonROS1 Positive (geneinterpretation)active2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.24.jsonStage IIICactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.240.jsonROS1 results (HGNC)active2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.241.jsonROS1 Gene Rearrangementactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.246.jsonRET Negative (geneinterpretaion) NCIactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.247.jsonRET Negative (geneinterpretaion) SNOMEDCT,NCIactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.248.jsonRET Fusion Molecular Variantsactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.25.jsonESR1 Gene Testactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.250.jsonRepotrectinib Value setactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.251.jsonAmivantamabactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.252.jsonAlectinib Drugactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.253.jsonGemcitabine Drug Value setactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.254.jsonvinorelbine Drugactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.255.jsonNSCLC_Tumor_resection SNOMEDCTactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.256.jsonNSCLC_Tumor_resection CPTactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.257.jsonNSCLC_Tumor_resection SNOMEDCT CPTactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.258.jsonALK results (HGNC)active2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.259.jsonALK Positive (geneinterpretation) SNOMEDactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.26.jsonESR1 Genetic Mutationactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.260.jsonALK Positive (geneinterpretation) NCIactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.261.jsonALK Positive (geneinterpretation) SNOMEDCT NCIactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.262.jsonALK Negative (geneinterpretation) SNOMEDCTactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.263.jsonALK Negative (geneinterpretation) NCIactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.264.jsonALK Negative (geneinterpretation) SNOMEDCT NCIactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.265.jsonLocoregional Sitesactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.266.jsonNSCLC N2 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.267.jsonNSCLC N1 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.268.jsonNSCLC N0 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.269.jsonNSCLC T3_T4 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.27.jsonGenetic Test Findingactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.270.jsonNSCLC T2 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.271.jsonNSCLC T1 Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.272.jsonLocally_Advanced_Metastatic_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.273.jsonLocalized_Inclusion_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.274.jsonLocalized_Exclusion_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.275.jsontarlatamab dlleactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.276.jsonExtensive SCLC Stage Group SNOMEDCTactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.277.jsonExtensive SCLC Stage Group NCIMactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.278.jsonExtensive SCLC Stage Groupactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.279.jsonLocalized SCLC Stage Groupactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.280.jsonSCLC M Stage (metastatic)active2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.281.jsonSCLC T Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.282.jsonSCLC N Stageactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.283.jsonSCLC histology (to include those patients)active2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.284.jsonBinimetinibactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.285.jsonEncorafenibactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.286.jsonEncorafenib PM Molecular variantactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.288.jsonBRAF Positive (geneinterpretation)active2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.289.jsonBRAF test (HGNC)active2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.292.jsonPrior therapy for Amivantamabactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.293.jsonENHERTU Drugactive2024-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.294.jsonMetastatic_Solid_Cancer_Stage Group SNOMED CTactive2024-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.295.jsonLocally_Advanced_Solid_Cancer_Stage Group SNOMED CTactive2024-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.296.jsonLocalized_Solid_Cancer_Stage Group SNOMED CTactive2024-071